MCRPC
Clinical trials for MCRPC explained in plain language.
Never miss a new study
Get alerted when new MCRPC trials appear
Sign up with your email to follow new studies for MCRPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation therapy targets hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called 177Lu-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The study has two phases: Pha…
Matched conditions: MCRPC
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated May 26, 2026 02:29 UTC
-
New drug combo targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see if it helps control the can…
Matched conditions: MCRPC
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 02:27 UTC
-
New radioactive drug targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug called [225Ac]Ac-AKY-2519 in people with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The drug targets a protein (B7-H3) on cancer cells to deliver radiation directly to tum…
Matched conditions: MCRPC
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC